Neurology

Despite the improvements, Lexeo was unable to discern a benefit on cardiovascular fitness and Peak VO2 from LX2006 with current measurements.

Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute, pointed out that genetic forms of PD are relatively well-understood compared to other types.

Review top news and interview highlights from the week ending July 12, 2024.

The chairman and chief executive officer of NKGen discussed the new clinical study design for evaluating the NK cell therapy in PD.

The BCT-006-US trial is set to begin dosing this year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Treated patients had a –0.2 mean change in cUHDRS compared with a –1.0 change in external control data.

The chairman and chief executive officer of NKGen discussed the mechanism behind the company’s NK cell therapy SNK01 and promising early results in patients with PD.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC also discussed current strategies with gene therapy administration.

Deborah Phippard, PhD, the chief scientific officer of Precision for Medicine, discussed unique difficulties of designing clinical trials for PD gene therapy candidates.

The chairman and chief executive officer of NKGen discussed the potential of SNK01, the company’s autologous natural killer cell therapy, in treating PD.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending July 5, 2024.

The therapy, rAAV-Olig001-ASPA, has shown positive clinical benefits in several interim updates from an ongoing, first-in-human phase 1/2 clinical trial (NCT04833907).

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The company has reported data in NMOSD, myasthenia gravis, and necrotizing myopathy over the last several months.

The associate professor of neurology at the Cleveland Clinic Lerner Institute discussed the challenges that will need to be overcome to apply gene therapy to a complex neurological disorder like PD.

The senior researcher at Seattle Children’s discussed advantages of engineered Tregs compared with natural Tregs.

Cartesian also announced that the first patient has been dosed in a separate clinical trial evaluating the CAR-T therapy in systematic lupus erythematosus.

The associate professor of neurology at the Cleveland Clinic Lerner Institute pointed out that genetic forms of PD may be the best place to start for new therapeutic research.

The placebo-controlled multidose portion of the SELECT-HD trial included 23 patients with Huntington Disease in total.

Various improvements were seen in 2 adult patients and 2 pediatric patients treated in separate clinical trials.

Review top news and interview highlights from the week ending June 28, 2024.

The cofounder and chief executive officer of Kate Therapeutics discussed research that awarded him an Outstanding New Investigator at the ASGCT 2024 meeting.